RXST · RxSight, Inc.
$6.14
+0.09 (+1.49%)
At close · Jul 29
Market Cap
$250.45M
Shares
41.40M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$134.48M
-3.9%
FY2025
Net Income
-$38.94M
-41.8%
FY2025
Gross Margin
76.6%
+5.9pp
FY2025
Operating Margin
-35.84%
-9.5pp
FY2025
Diluted EPS
-$0.95
-33.8%
FY2025
Operating Cash Flow
-$15.51M
+8.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $127.48M | $134.48MG | $139.93M | $89.08M | $49.01M | $22.59M | $14.68M | |
| $29.3M | $31.47M | $40.98M | $35.31M | $27.68M | $18.08M | $12.97M | |
| $98.18M | $103.01M | $98.94M | $53.77M | $21.33M | $4.52M | $1.71M | |
| — | 76.6% | 70.71% | 60.36% | 43.52% | 19.99% | 11.62% | |
| $37.65M | $38.55M | $34.37M | $29.05M | $25.98M | $24.5M | $21.93M | |
| $115.87M | $112.65M | $101.43M | $74.8M | $58.67M | $32.81M | $15.18M | |
| — | $3.27M | $3.58M | $4.08M | $3.88M | $3.98M | $3.85M | |
| $153.52M | $151.2M | $135.8M | $103.85M | $84.65M | $57.3M | $37.12M | |
| -$55.35M | -$48.19M | -$36.86M | -$50.09M | -$63.32M | -$52.79M | -$35.41M | |
| — | -35.84% | -26.34% | -56.23% | -129.21% | -233.64% | -241.26% | |
| — | -$44.93M | -$33.28M | -$46.01M | -$59.43M | -$48.81M | -$31.56M | |
| $16K | $19K | $21K | $3.31M | $4.95M | $3.68M | $510K | |
| -$46.58M | -$38.88M | -$27.41M | -$48.59M | -$66.75M | -$48.68M | $27.63M | |
| $54K | $66K | $50K | $20K | $9000 | $8000 | $57K | |
| -$46.64M | -$38.94M | -$27.46M | -$48.61M | -$66.76M | -$48.69M | $27.58M | |
| — | -28.96% | -19.62% | -54.57% | -136.22% | -215.5% | 187.87% | |
| — | — | — | — | — | -$48.69M | $3.37M | |
| -$46.72M | -$39.06M | -$27.28M | -$48.52M | -$66.83M | -$48.71M | $27.53M | |
| USD/shares | — | -$0.95 | -$0.71 | -$1.41 | -$2.41 | -$3.57 | $0.91 |
| USD/shares | — | -$0.95 | -$0.71 | -$1.41 | -$2.41 | -$3.57 | $0.15 |
| shares | — | 40.85M | 38.87M | 34.46M | 27.66M | 13.63M | 3.71M |
| shares | — | 40.85M | 38.87M | 34.46M | 27.66M | 13.63M | 5.53M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.55×
EV/EBIT
—
Peer median 20.01×
P/E (TTM)
—
Peer median 30.60×
Peer medians compare against the 86 similar-size Medical Devices companies (of 146 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Rxlal | $108,062,000 | $96,497,000 | $54,092,000 | $24,965,000 | — | $4,256,000 |
| LDD | $20,669,000 | $39,704,000 | $32,091,000 | $22,515,000 | $13,774,000 | $10,159,000 |
| Service Warranty Service Contracts and Accessories | $5,748,000 | $3,726,000 | $2,894,000 | $1,525,000 | $656,000 | $263,000 |
| Additions During the Period | — | — | — | — | $793,000 | — |
| Balance at Beginning of Period | — | — | — | — | $540,000 | $345,000 |
| Balance at End of Period | — | — | — | — | $540,000 | — |
| LAL | — | — | — | — | $8,163,000 | — |
| Revenue Recognized During the Period | — | — | — | — | -$598,000 | — |
Key facts
CIK
1111485
CUSIP
78349D107
13F (30d)
21 filings
21 filers
Visit website
Investor relations